Molecular Oncology (Nov 2023)

A protein complex of LCN2, LOXL2 and MMP9 facilitates tumour metastasis in oesophageal cancer

  • Qiaoxi Xia,
  • Zepeng Du,
  • Mantong Chen,
  • Xiao Zhou,
  • Wenjing Bai,
  • Xiaoqi Zheng,
  • Ling Lin,
  • Yan Zhao,
  • Jiyu Ding,
  • Zhisheng Wu,
  • Haiying Zou,
  • Shaohong Wang,
  • Liyan Xu,
  • Enmin Li,
  • Bingli Wu

DOI
https://doi.org/10.1002/1878-0261.13529
Journal volume & issue
Vol. 17, no. 11
pp. 2451 – 2471

Abstract

Read online

During malignant tumour development, the extracellular matrix (ECM) is usually abnormally regulated. Dysregulated expression of lysyl oxidase‐like 2 (LOXL2), matrix metalloproteinase 9 (MMP9) and lipocalin 2 (LCN2) are associated with ECM remodelling. In this study, protein–protein interaction assays indicated that LCN2 and LOXL2 interactions and LCN2 and MMP9 interactions occurred both intracellularly and extracellularly, but interactions between LOXL2 and MMP9 only occurred intracellularly. The LCN2/LOXL2/MMP9 ternary complex promoted migration and invasion of oesophageal squamous cell carcinoma (ESCC) cells, as well as tumour growth and malignant progression in vivo, while the iron chelator deferoxamine mesylate (DFOM) inhibited ESCC tumour growth. Co‐overexpression of LCN2, LOXL2 and MMP9 enhanced the ability of tumour cells to degrade fibronectin and Matrigel, increased the formation and extension of filopodia, and promoted the rearrangement of microfilaments through upregulation of profilin 1. In addition, the LCN2/LOXL2/MMP9 ternary complex promoted the expression of testican‐1 (SPOCK1), and abnormally activated the FAK/AKT/GSK3β signalling pathway. In summary, the LCN2/LOXL2/MMP9 ternary complex promoted the migration and invasion of cancer cells and malignant tumour progression through multiple mechanisms and could be a potential therapeutic target.

Keywords